Our previous studies further explored the potential role of kokusaginine in the clinical treatment of renal fibrosis, showing that it can effectively inhibit the activation of the PI3K/AKT signaling pathway, thereby preventing the formation of renal fibrosis in vivo and in vitro [10]. Here, AKT1 is linked to renal fibrosis.